Mark Lovern
Impact in
- Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria
Papers in
-
- Pneumonia and Respiratory Infections 4
- Influenza Virus Research Studies 2
- Hepatitis B Virus Studies 1
- Co-authors
- Timothy J. Carrothers (4 shared papers)Todd Riccobene (4 shared papers)Paul M. Schlosser (1 shared paper)Shampa Das (2 shared papers)Lena E. Friberg (1 shared paper)Maria Laura Sargentini‐Maier (1 shared paper)Armel Stockis (1 shared paper)Benoît Lacroix (1 shared paper)
- Journals
- Clinical Pharmacology & Therapeutics (3 papers)Carcinogenesis (2 papers)Antimicrobial Agents and Chemotherapy (2 papers)British Journal of Clinical Pharmacology (1 paper)Drug Metabolism Reviews (1 paper)
- Partner nations
- United StatesUnited KingdomBelgium
In The Last Decade
Mark Lovern
20 papers receiving 493 citations
Peers
Comparison fields: 5 of 90
- Molecular Medicine 92
- Applied Microbiology and Biotechnology 13
- Pharmacology 100
- Genetics 57
- Internal Medicine 13
Countries citing papers authored by Mark Lovern
This map shows the geographic impact of Mark Lovern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lovern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lovern more than expected).
Fields of papers citing papers by Mark Lovern
This network shows the impact of papers produced by Mark Lovern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lovern. The network helps show where Mark Lovern may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Lovern, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 80 | |
| 2 | 2021 | 77 | |
| 3 | 1997 | 51 | |
| 4 | 2009 | 51 | |
| 5 | 2002 | 47 | |
| 6 | 2022 | 35 | |
| 7 | 2001 | 34 | |
| 8 | 2021 | 29 | |
| 9 | 2011 | 28 | |
| 10 | 2020 | 27 | |
| 11 | 2021 | 21 | |
| 12 | 1999 | 18 | |
| 13 | 2009 | 4 | |
| 14 | 2022 | 3 | |
| 15 | 2014 | 3 | |
| 16 | 2019 | 2 | |
| 17 | 2017 | 2 | |
| 18 | Pharmacokinetic and Pharmacokinetic/ Pharmacodynamic Modeling to Inform Optimal Dose of Vorapaxar | 2015 | 1 |
| 19 | 2023 | 1 | |
| 20 | 2022 | 1 |
About Mark Lovern
Mark Lovern is a scholar working on Epidemiology, Molecular Biology, Pharmacology, Molecular Medicine and Infectious Diseases, having authored 21 papers that have together received 515 indexed citations. Recurring topics across this work include Pneumonia and Respiratory Infections (4 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers), Antibiotic Resistance in Bacteria (4 papers), Carcinogens and Genotoxicity Assessment (3 papers), Pharmacogenetics and Drug Metabolism (3 papers), Influenza Virus Research Studies (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and Hepatitis B Virus Studies (1 paper). The work is most often cited by research in Molecular Medicine (92 citations), Applied Microbiology and Biotechnology (13 citations), Pharmacology (100 citations), Genetics (57 citations) and Internal Medicine (13 citations). Mark Lovern has collaborated with scholars based in United States, United Kingdom and Belgium. Frequent co-authors include Timothy J. Carrothers, Todd Riccobene, Paul M. Schlosser, Shampa Das, Lena E. Friberg, Maria Laura Sargentini‐Maier, Armel Stockis, Benoît Lacroix, Yuan Xiong and Mats O. Karlsson. Their work appears in journals such as Clinical Pharmacology & Therapeutics, Carcinogenesis, Antimicrobial Agents and Chemotherapy, British Journal of Clinical Pharmacology and Drug Metabolism Reviews.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.